<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 367 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page366.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=367">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 367 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 367</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=367"><img src="../thumb/367.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>330 / 2020-04                                                          Immunological - 24.1 / 24.2
   of Tysabri use in case of any infect., pts.can switch direct.from beta   (S4) INJ, 30/34/0185, 0186
   interfer./glatiramer acetate to Tysabri prov.there are no signs of relev.   24.2  Immunostimulants  700474-003: 9,6 mill.IU(0,3 mg)/vial, 15 x 3  ml vials +15 pre-fill.sy-
   treatm.-relat.abnormalit.e.g. neutropenia                  ring.of dil., R7 599,99
   See also MDR page 468.       AVONEX (MDR Listing)          Dosage: Adults: Recomm.dos: 8 mill.IU (0,25 mg) contain.in 1 ml
   XOLAIR, Novartis [P/S]       PLEGRIDY (MDR Listing)        of reconstit.sol inj.SC every other day. Dos.titrat.recomm.init.start.at
                                REBIF (MDR Listing)
                                                              0,0625 mg (0,25 ml) SC every other day incr.slow.to 0,25 mg (1,0 ml)
   Omalizumab                                                 every other day. Titr.per.may be adjust.to indiv.toler.
   Indications: Prevent.of asthma exacerbat. & contr.of asthma   AVONEX, Litha [P/S] &  Contraindications: Hypersens.hist.incl.human albumin, pregn.,
   sympts. in adults & adolesc.≥12 yrs.as add-on ther.for pts.with sev.  Inteferon beta-1a.  safety & effic.in childr.und.18 yrs. not est.
   persist. allerg. asthma with pos.skin test/in vitro reactiv.to perenn.   Indications: Pts.diagnos.with relaps.multiple sclerosis (MS)  char-  Side effects: Pancreatit.freq.assoc.with hypertriglyceridaem.,
   aeroallerg. & reduc.lung funct. (FEV 1 &lt;80%) as well as freq.day-time   acteris. 2 or more relapses in prev. 3 yrs.; pts. with single demyeli-  flu-like sympts., inj.site reacts. incl. necros., bld.dyscras., lymphad-
   sympts./night-time awaken.& mult.sev.asthma exacerbat.desp.dly   nat.event with act. inflammat.proc.if sev.enough to warrant treatm.   enopathy, CNS effs., headache, hypertens., skin reacts., myalg., hy-
   high-dos.corticoster. & inhal.β 2-agon., add-on ther.to reduc.dos.of   with IV corticoster./if alternat. diagnos. excl & if are determin.to be   perton., urin. urgen., impot., metrorrhag., chest pain, malaise, periph.
   inhal.corticoster.in childr.6-11 yrs with sev.persist.allerg.asthma   at high risk of develop. clinic. definite MS; slows progress.of disabil-  oed., asthen., anaphylact.reacts., thyroid dysfunct., anorex., weight
   with pos.skin test/in vitro reactiv.to perenn.aeroallerg.as well as   ity & decr. freq. of relapses.  chang., psych.disords., convuls., dizzin., cardiomyopathy, tachycard.,
   freq.day-time sympts./night-time awaken.; chron. spontan.urticaria   (S4) SOL FOR INJ. A40/34/0502. 6 mill.iu (30 µg)/ 0,5 ml  palpitat., vasodilat., bronchosp., GI disturbs., hepat. inj./fail., alopec.,
   (CSU) refract.to std.of care in adults & adolesc.≥12 yrs.  712306-001: 4x1 ml pre fill syr., R7 640,00  arthralg., menstr.disords., sweat.
   (S4) POWD.FOR SOL.FOR INJ, A39/34/0311.  Dosage: 30 µg IM once a wk. Vary inj.site wkly. SC admin.cannot   Warnings and special precautions: Capill.leak syndr.in pre-exist.
   720829-001: 125 mg/ml (reconstit), 1 vial, R4 967,76  be substitut.for IM admin. Remove from refrige.& allow to warm to   monoclon.gammopathy, depress. & suicid.ideation a poss.S/E & pts.
   Dosage: For SC admin.only., do not mix with any meds./diluents   room temp for 30 mins.& use within 12 hrs. Currently no exper. be-  to be warn.& advis.to report sympts.immed., prev.or curr. depress.
   other than ster.H 2O for inj.  yond 2 yrs.of treatm.       disords./suic.ideat., vir.dis.transmiss. risk, seiz. hist., immunogenic-
   Allergic asthma: Refer to prod.lit. for dos. determin. Charts. Do   Contraindications: Pregn.& lactat., sev.depress. disords. & suicid.  ity potent., concom immunomodulat. other than corticoids/ACTH not
   not admin.to pts.whose baseline IgE lev./bw are outside of dos.  ideation, inadeq.control.epilep., childr.  recomm., concom.meds.aff.haematopoet.syst., women of childbear.
   table limits. Approp.dos.& dos.freq.determ.by body weight   Side effects: Trans.neurolog.sympts.mimic MS exacerabat., trans.  potent., inform pt.of potent. hazard & recomm.to discont.ther.should
   & baseline IgE measured bef.start of treatm.  hyperton. &/or sev.musc. weakn. V.comm: Flu-like sympts., head-  a woman become pregn./plan pregn., potent.ser.adverse react. risk in
   Dosage range: 75-600 mg in 1-4 injects.may be need.for each   ache, pyrex., chills, sweat. Comm: Decr.lymphoc/WBC/ neutroph.  inft.theref.discont.dur.lactat., meds. assoc.with hepatoxic./comorbid
                                              +
   admin.                       count, decr.haematocrit, incr.bld.K & urea nitrog., musc.spastic., hy-  med.condits., monit.ser.transamin.lev.& discont.ther.if clinic. sympt.
   Pts. with IgE &lt; 76 UI/ml.unlikely to exper.benef. & phys. to ensure   poesthaes., rhinorrh., N&V, diarrh., rash, incr.sweat., contus., musc.   ie.jaund., monit.pre-exist.card.disords.esp. dur.init.ther., discont.
   these pts.have unequivoc. in vitro react.to perenn.allerg.bef.start.  cramp, neck/back pain, myalg., arthralg., extrem. pain, musc.-/mus-  treatm.if cardiomyopathy link.to ther.occurs,, advise pt.to seek medic.
   ther.; assess treatm.effic.at 16 wks.aft.commenc.treatm.bef. furth.  culoskelet.stiffn., anorex., flush., inj.site pain/erythema & bruis.,   advice in event of broken skin at inj.site., asept.inj. techniq. & rotate
   injects.admin.; re-test.of IgE lev.dur.treatm. cannot be used as guide   asthen., pain, fatig., malaise, night sweats, depress., insomn. Un-  sites, myelosuppress., monit.ren. funct.in pts.who devel.neutropen./
   for dos.determinat.as total IgE lev.are elev.dur.ther.& remainelevat.  comm: Decr.platel.count, alopec., inj.site burn., metorrhag., menor-  fev./infect., bld. exam.bef.init.& dur.ther.advis., thyroid dysfunct. hist.
   for up to 1 yr.aft.discont.; dos.determin.aft.treatm. interrupt.&lt;1yr. to   rhag. Rare: Thrombot. microangiopathy incl.TPP/haemolyt.uraem.  Interactions: Concom.drugs with narr.therap. index largely depend.
   be based on ser.IgE lev.obtain.at init. dos.determinat.; re-test.total   syndr., dyspn, nephrot.syndr., glomeruloscleros. Not known: Decr./  on hepat.cytochrome P450 syst.clear.
   ser.IgE for dos. determinat.if treatm.interrupt.&gt;1yr.; dos.should be   incr.weight, abnorm.LFT, cardiomyopathy, CHF, palpitat., dysrhythm.,
   adjust.for signif.changes in BW.  tachycard., pancytopen., thrombocytopen., neurolog. sympt., syncope,   COPAXONE, (Cipla Medpro) Teva [P/S]
   Chron.spontan.urticaria: Dos.not depend.on serum total IgE/  hyperton., dizzin., paraesthes., seiz., migraine, pulm.arter.hypertens.,   Glatiramer.
   body weight. Recomm.dos: 300 mg SC every 4 wks. Some pts.  prurit., vesic.rash, urticar., psorias.aggrav., SLE, musc. weakn., arthrit.,   Indications: Reduc.relapse freq.in ambulat.pts. with relaps.remitt.
   may achieve sympt.contr.on 150 mg every 4 wks.  hypo-/hyperthyroid., inj.site abscess/-react./-inflammat/-cellulit.  multiple scleros.charact.by at least 2 neurolog.dysfunct.attacks over
                                necros/-bleed., vasodilat., chest pain, anaphylact.react./-shock., hy-
   Contraindications: Treatment of ac.asthma exacerbats./     preced.2 yr.period. It is NOT indicat.in prim./second. progress.MS
   ac.bronchosp./stat.asthmatic./ hyperimmunoglob.E syndr./allerg.  persens., hepat.fail., suicide, psychos., anx., confus., emot.labil., hep-  (S4) SOL FOR INJ. A40/34/0258.
                                atit., autoimmune. hepatit.
   bronchopulmon. aspergillos./ prev.of anaphylact.reacts.incl.those   708286-001: 20 mg/pre-fill.syr., 28x1 ml pre-fill. syr., R7 500,00
   provok.by food allerg., safety in pregn./lactat.not est., IV/IM inj.,   Warnings and special precautions: Discont.if prog. multiple   Dosage: Initit.of treatm.supervis.by neurolog./ exper.physic. Pts.to be
                                scleros.devel., hist.of seiz.& depress., pts.without pre-exist.seiz.
   allerg.asthma: childr.&lt;6yrs., CSU: childr.&lt;12 yrs.  disord.develop. seiz. dur.ther., depress.& suicid.ideation a poss.   instruct.on self-inj. techniq. und.prof.healthcare supervis.
   Side effects: Anaphylax., bronchosp., hypotens., syncop., urticar.,   S/E & pts.to be warn.& advis.to report sympts. immed., assess pts.  Adults: Recomm.dos: 20 mg admin.SC once dly. Long-term treatm.
   angioed., ser.sickn./-like reacts., system.hypereosinophil.syndr./  develop.dyspn./fatig.for pulm. arter.hypertens., monit.periodic.for   to be decid.on indiv.basis.
   allerg.eosinophil. granulomat. vasculit., inj.site reacts., headache,   early S&S of nephrot. syndr.incl.oed./proteinur/imp.ren.funct. esp.   Contraindications: Mannitol hypersens., pregn.
   pyrex., abdom.pain., parasit.infects., ser.allerg. condits., anti-ther-  in pts.at high.risk of ren.dis., treat.nephrot. syndr.prompt.& consid.  Side effects: Immed.post-inj.react.of at least one/ more follow.
   apeut.antibody developm., paraesthes., somnol., dizzin., post.hypo-  discont., prompt treatm.req.if thrombot.microangiopathy diagnos.&   sympts.of vasodilat./chest pain/ dyspn./palpitat.or tachycard., loc.
   tens., flush., pharyngit., cough, laryngoed., GI disords., photosens.,   immed. discont.is recomm., concom.drugs with narr. therapeut. in-  reacts., flu syndr., asthen., back/flank/neck pain, headache, allerg.re-
   rash, prurit., influenza-like illn., swell. of arms/joints, incr.weight,   dex largely depend.on hepat. cytochrome P450 syst.clear., monit.  acts., chills., fac.oed., fev., malaise, neoplasm, suic.attempt., hangover
   fatig., idiopath.sev. thrombocytopen., alopec., arthralg., myalg.,   pts.for signs of hepat.inj.when used concom.with meds assoc.  eff., hernia, hypotherm., inflammat.nose, muc.membr. disord., post
   extremity/ musculoskelet.pain, nasopharyngit., sinusit., viral URTI,   with hepat. injur., adeq.contracept.in fert.women, advice to be giv.  vaccinat.syndr., syncope, hypertens., migraine, vasc.disord., pallor,
   UTI, arter.thrombot.effs.incl.MI.  of potent.hazards to foetus., admin. und. medic supervis., pts may   varicose vein, GI disturbs., tooth disords., oesophag.ulc., rect. haem-
   Warnings and special precautions: Only consid. treatm.in   self inj.if physic. determ.it is appropr.aft prop.train., admin. analag.   orrh., hepatomegaly, saliv.gland enlargem., goitre, hyperthyroid., ec-
   pts.with convinc.IgE mediat. asthma., observ.closely for approp.  antipyret.prior to inj.& x24 hrs.thereaft.to decr.flu-like sympts., no   chymos., lymphadenopathy, eosinophil., splenomegaly, oed., weight
   period aft. admin. as anaphylax.poss.& discont.in case of sev.   exper.in pts.18 yrs.or less, eval.aft.2 yrs. treatm. & long.treatm.to   gain, alcoh.intol., gout, arthralg., arthrit., tend.disord., hyperton., CNS
   hypersens., inform.pt.of anaphylax.S&S and to seek med.care   be decid.on indiv. bas., sev.ren.& hepat.fail., sev. myelosuppress.,   effs., hostility, man.reacts., myoclon., neurit., personality disord., torti-
   should sympts.occ., use in atop. dermatit./ allerg.rhinit./pts.with   flu-like sympts.most promin.with init. ther.decr.in freq.with cont.  collis, bronchit., incr. cough, rhinit., apnoea, epistax., laryngism., lung
   autoimmun.dis./ immune complex-mediat.condits./pre-exist.ren.  treatm., ability to drive/operat machin.poss.affect., anti-epilept.   disord., voice alterat., hyperventilat., skin reacts. incl. H.simplex/skin
   or hepat. impairm., abrupt discont.of system./inhal. corticoster. aft.  treatm.partic.if epilep.not adeq.control., monit.pts with pre-exist.  benign neoplasm/ furunculos./ skin atrophy & skin nodules, diplop.,
   init.Xolair not recomm., discont.in case of sev.system.eosinophil.&   card.dis.closely for clinic.worsen. dur. treatm.,, abortifacient po-  ear & eye disord., otit.med.& externa, vis. disturbs., oral/ vag. mon-
   vasculit., pts.at high risk of helminth infects.& discont.if respon.to  tent., monit.of bld. counts & chem.& liv.funct.tests recomm., pts.  ilias., cataract specif. corn. les., eye haemorrh., mydrias., ptos., vertigo,
   recomm. anti-helminth treatm.inadeq., diabet. mellit./ fruct.intol/   with myelosuppress. may req.more intens.monitor.of complete bld.  cystit., dysmennorrh., impot., menstr.disord., suspic. pap.smear, urin.
   gluc.-galact.malabsorpt.syndr./ sucrose-isomaltase defic.to be   cell counts with different. & platelet counts, pos.antibod.developm.  disords., abort., breast enlargem., ovar.disord., priap., prostat./testis
   warn.of sucrose content.     to Avonex with reduc.clin.effic.  disord., vag.haemorrh., vulvovag.disord., anaphylact. reacts., convuls.
                                                              Warnings IM/IV admin., safety & effic.not est.in pts.bel.18 yrs., not
   ZAPRINE 50, Hexal [P/S]      See also MDR page 444.        stud.in elderly, advis.pts.of poss. immed.post-inj.reacts., consid.con-
   Azathioprine.                BETAFERON, Bayer [P/S]        com. contracept.cover, eval.risk vs.benef.in nurs. mothers, pre-exist.
   Indications: Immunosuppress.in organ transplants, therapeut.eff.  Lyophilised inteferon beta-1b  card.disord., ren.impairm.
   in cert.auto-immune  dis.when condit.refract.to corticoster./when   Indications: Sngl.clinic.event suggest.of multiple scleros.to de-  Drug interactions: No form.evaluat., as in-vitro work suggests it’s
   corticoster.dos.produc.sev.side-effs.  lay progress.to defin.multiple scleros. & sustain.neurolog.disabil.,   high.plasma prot.bound. monit. concom.prot.bound subst.
   (S4) TABS. 34/26/0444        relapsing-remitt. multiple sclerosis in ambulatory pts., second. pro-
   700777-007: 50 mg, 100, R899,51  gress. multiple scleros.  MOZOBIL, Sanofi-Aventis
   Dosage: Transplantat: Indiv. Load.dos: 1-5 mg/kg bm/day. Maint.:   Plerixafor
   1-4 mg/kg bm/day                                           Indications: Enhanc.mobilisat.of hematopoiet. stem cells (HSCs)
   Auto-immune dis: Indiv.accord.to sev.& clinic. respons. Usual   to the periph.bld.for collect & subseq. autolog.transplantat.in pts.
   dos: 1-2,5 mg/kg bm/day. Act. chron. hepatit: 1-2 mg/kg bm/day.  with lymphoma & multiple myeloma (MM)
   Contraindications: 6 Mercaptopurine hypersens., pregn., safety   Certain medicines (i.e.   (S4) SOL.FOR INJ, 44/32.2/0546. 20 mg/ml.
   in lactat.not est.                  those that cause CNS   715940-001: 24 mg, 1x1,2 ml vial, R98 363,55
   Side effects: Bone marrow depress., haematopoies., allerg. re-  Dosage: Do not mix.with other med.prods.in same inj.
   acts., GI disturbs., negat. N 2 bal., drug fev., ser. sickn., pulm.oed.,   depression) may lead to   Recomm.dos: 0,24 mg/kg BW by SC inj. 6-11 hrs prior to
   revers. pneumonit., periton. haemorrh., retinopathy, alopec., ath-  apheresis follow. 4 days of treatm.with G-CSF. Use for 2-4 (up to
   ralg., Raynauds, hyperuricaem., ac.ren. fail., hyperphosphataem.,   drowsiness and impaired   7) consecut.days.
   skin pigmentat., poss. suppress. of ovar.& testic.funct., bld.dyscras.  concentration, which   Dose in ml = 0.012 x act. BW (kg) (obtain.weight within 1 wk of
   Special precautions: Consid.tetratogen.potent. in males/females   1st dos.)
   if pregn.poss.dur.ther., excret.in breast milk, imp.ren./hepat.funct., in   may be aggravated by   Contraindications: Pregn/lactat., not intend.for use in pts. with
   auto-immune dis. if no discern.improvem.evid.aft.3 mnths. consid.   leukaem.
   discont., compl.bld.counts.dur.1  8 wks.of ther., infect.risk., mani-  the simultaneous intake   Side effects: Extrasystol., vertigo, eye swell., GI disords., inj.
                st
   festat.of bone marr. depress., neoplas.vunerability, avoid.meds.  of alcohol or other   site reacts., fatig., malaise, asthen., influenza like illn., irritab.,
   with myelosuppress.eff.                                    procedur.hypertens./ naus., incr.aspartate aminotransfer., decr.
   Drug interactions: Eff.enhanc.by allopurinol/ oxipurinol &thio-  central nervous system   appet., hypocalcaem., hyponatraem., hypophosphataem., arthralg.,
   purinol, neuromusc.block.of depolaris. agents potent.& block.of   musculoskelet.pain/stiffn., musc. weakn., neck pain, headache,
   non-polaris. agents reduc., poss.myelosuppress.effs.of cimetid.   depressant agents.  dizzin., dysgeus., insomn., anticipat.anx., anx, nightmare, pollakiur.,
   enhanc., meds.affect.leucocyt.product.incl.co-trimoxaz. may exag-  sin. congest., hyperhidros., erythem., cold sweat, ecchymos.,
   ger.leucopen., sev.leucopen. poss.with ACE inhibit.        hypoaesthes.fac., night sweats, urticar., flush., hypotens., spleen</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page366.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>
             </td>
             <td width="35%"><a href="page368.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page368.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
